DEXWireNews

PGNX - Bullish Momentum Found - Bullish RSI Seen

Long
NASDAQ:PGNX   None
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

SHORT INTEREST
10M 07/31/19

P/E Current
-4.44

P/E Ratio (with extraordinary items)
-4.23

Average Recommendation: BUY

Average Target Price: 9.38

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our App on Google Play! dexwirenews.com/APP

2) Text Message Notifications: dexwirenews.com/SMS

3) Telegram: t.me/DEXWireNews

4) Follow Us on our Social Networks
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.